• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗肺血清导致的呼吸衰竭:与表面活性剂系统损伤相关机制的研究

Respiratory failure following anti-lung serum: study on mechanisms associated with surfactant system damage.

作者信息

Lachmann B, Hallman M, Bergmann K C

出版信息

Exp Lung Res. 1987;12(2):163-80. doi: 10.3109/01902148709062839.

DOI:10.3109/01902148709062839
PMID:3569167
Abstract

Within 2 minutes intravenous anti-lung serum (ALS) into guinea pig induces a respiratory failure that is fatal within 30 min. The relationship between surfactant, alveolar-capillary permeability and respiratory failure was studied. Within two minutes ALS induced a leak in the alveolar-capillary barrier. Within 30 minutes 28.3% (controls, given normal rabbit serum: 0.7%) of iv 131I-albumin, and 0.5% (controls 0.02%) of iv surfactant phospholipid tracer were recovered in bronchoalveolar lavage. Furthermore, 57% (controls 32%) of the endotracheally administered surfactant phospholipid became associated with lung tissue and only less than 0.5% left the lung. The distribution of proteins and phospholipids between the in vivo small volume bronchoalveolar lavages and the ex vivo bronchoalveolar lavages were dissimilar: 84% (controls 20%) of intravenously injected, lavageable 131I-albumin and 23% (controls 18%) of total lavageable phospholipid were recovered in the in vivo small volume bronchoalveolar lavages. ALS also decreased lavageable surfactant phospholipid by 41%. After ALS the minimum surface tension increased. The supernatant of the lavage increased the minimum surface tension of normal surfactant. In addition, the sediment fraction of the lavage had slow surface adsorption, and a marked reduction in 35,000 and 10,000 MW peptides. Exogenous surfactant ameliorated the ALS-induced respiratory failure. We propose that inhibition, altered intrapulmonary distribution, and dissociation of protein and phospholipid components of surfactant are important in early pathogenesis of acute respiratory failure.

摘要

在2分钟内给豚鼠静脉注射抗肺血清(ALS)可诱发呼吸衰竭,30分钟内致命。研究了表面活性剂、肺泡-毛细血管通透性与呼吸衰竭之间的关系。2分钟内ALS导致肺泡-毛细血管屏障渗漏。30分钟内,支气管肺泡灌洗回收了静脉注射的131I-白蛋白的28.3%(对照组给予正常兔血清:0.7%),以及静脉注射的表面活性剂磷脂示踪剂的0.5%(对照组0.02%)。此外,经气管内给予的表面活性剂磷脂有57%(对照组32%)与肺组织结合,只有不到0.5%离开肺部。体内小容量支气管肺泡灌洗与体外支气管肺泡灌洗之间蛋白质和磷脂的分布不同:静脉注射的、可灌洗的131I-白蛋白的84%(对照组20%)和可灌洗的总磷脂的23%(对照组18%)在体内小容量支气管肺泡灌洗中被回收。ALS还使可灌洗的表面活性剂磷脂减少了41%。ALS后最小表面张力增加。灌洗上清液增加了正常表面活性剂的最小表面张力。此外,灌洗的沉淀物部分表面吸附缓慢,35000和10000分子量的肽明显减少。外源性表面活性剂改善了ALS诱发的呼吸衰竭。我们提出,表面活性剂的抑制、肺内分布改变以及蛋白质和磷脂成分的解离在急性呼吸衰竭的早期发病机制中很重要。

相似文献

1
Respiratory failure following anti-lung serum: study on mechanisms associated with surfactant system damage.抗肺血清导致的呼吸衰竭:与表面活性剂系统损伤相关机制的研究
Exp Lung Res. 1987;12(2):163-80. doi: 10.3109/01902148709062839.
2
Surfactant abnormality after endotoxin-induced lung injury in guinea-pigs.豚鼠内毒素诱导性肺损伤后的表面活性剂异常
Eur J Respir Dis. 1987 Oct;71(4):250-8.
3
Endobronchial surface active phospholipids in various pulmonary diseases.各种肺部疾病中的支气管内表面活性磷脂
Eur J Respir Dis Suppl. 1985;142:37-47.
4
Interaction of transferrin saturated with iron with lung surfactant in respiratory failure.
J Appl Physiol (1985). 1994 Aug;77(2):757-66. doi: 10.1152/jappl.1994.77.2.757.
5
Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure.急性呼吸衰竭单纯病程及合并败血症病程中肺表面活性物质的改变。
J Trauma. 1990 Jan;30(1):19-26. doi: 10.1097/00005373-199001000-00003.
6
Pulmonary surfactant composition early in development of acute lung injury after cardiopulmonary bypass: prophylactic use of surfactant therapy.体外循环后急性肺损伤早期的肺表面活性物质组成:肺表面活性物质治疗的预防性应用
Int J Exp Pathol. 1997 Aug;78(4):277-89. doi: 10.1046/j.1365-2613.1997.330364.x.
7
Lung surfactant phospholipids in the foetus, newborn, and in the adult; evidence of abnormality in respiratory failure.胎儿、新生儿及成人肺表面活性物质磷脂;呼吸衰竭时异常的证据
Ann Chir Gynaecol Suppl. 1982;196:19-23.
8
Mechanisms of surfactant dysfunction in early acute lung injury.早期急性肺损伤中表面活性剂功能障碍的机制
Exp Lung Res. 1997 May-Jun;23(3):171-89. doi: 10.3109/01902149709087366.
9
Endotoxin induces respiratory failure and increases surfactant turnover and respiration independent of alveolocapillary injury in rats.内毒素可诱发大鼠呼吸衰竭,并增加表面活性剂更新率及呼吸频率,且与肺泡毛细血管损伤无关。
Am J Respir Crit Care Med. 2002 Jun 1;165(11):1516-25. doi: 10.1164/rccm.2012030.
10
Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A.特发性肺纤维化。支气管肺泡灌洗中表面活性蛋白A含量异常。
Am Rev Respir Dis. 1991 Jul;144(1):160-6. doi: 10.1164/ajrccm/144.1.160.

引用本文的文献

1
Surfactant therapy for acute lung injury and acute respiratory distress syndrome.表面活性物质治疗急性肺损伤和急性呼吸窘迫综合征。
Crit Care Clin. 2011 Jul;27(3):525-59. doi: 10.1016/j.ccc.2011.04.005.
2
Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.急性肺损伤和急性呼吸窘迫综合征的药物治疗
Curr Med Chem. 2008;15(19):1911-24. doi: 10.2174/092986708785132942.
3
Surfactant for pediatric acute lung injury.用于小儿急性肺损伤的表面活性剂
Pediatr Clin North Am. 2008 Jun;55(3):545-75, ix. doi: 10.1016/j.pcl.2008.02.016.
4
The fate of exogenous surfactant in neonates with respiratory distress syndrome.新生儿呼吸窘迫综合征中外源性表面活性剂的转归
Clin Pharmacokinet. 1994 Mar;26(3):215-32. doi: 10.2165/00003088-199426030-00005.
5
In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function.人血浆对外源性表面活性剂功能抑制能力的体内评估。
Intensive Care Med. 1994;20(1):6-11. doi: 10.1007/BF02425047.
6
Exogenous surfactant treatment for the adult respiratory distress syndrome? A historical perspective.外源性表面活性剂治疗成人呼吸窘迫综合征?历史视角。
Thorax. 1990 Nov;45(11):825-30. doi: 10.1136/thx.45.11.825.
7
Ventilation and secretion of pulmonary surfactant.肺表面活性物质的通气与分泌
Clin Investig. 1992 Jan;70(1):3-13. doi: 10.1007/BF00422930.